The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Alpha-synuclein oligomers: a new hope
Open accessAbstract
Alpha-synuclein is a protein implicated in Parkinson's disease and thought to be one of the main pathological drivers in the disease, although it remains unclear how this protein elicits its neurotoxic effects. Recent findings indicate that the assembly of toxic oligomeric species of alpha-synuclein may be one of the key processes for the pathology and spread of the disease. The absence of a sensitive in situ detection method has hindered the study of these oligomeric species and the role they play in the human brain until recently. In this review, we assess the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discuss the advances in our understanding of the role of alpha-synuclein in Parkinson's disease that may be brought about by the specific and sensitive detection of distinct oligomeric species in post-mortem patient brain. Finally, we discuss current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., Rohn, T. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019338 · Cited by 423
RetractedSpencer, B. J., Williams, S. M., Rockenstein, E. M., Valera, E., Xin, W., Mante, M., Florio, J. B., Adame, A., Masliah, E., & Sierks, M. R. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.321 · Cited by 47
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Neuropathological examination of Parkinson’s disease progression suggested that a-syn pathology spreads through the nervous system following stereotyped patterns [12], which first led to the suggestion of a pathogenic agent ‘propagating’ through the nervous system.”
BackgroundSpillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“First, a genetic link was found to associate a-syn to Parkinson’ disease; the point mutation in SNCA (A53T) was demonstrated to cause autosomal dominant Parkinson’s disease [126] and several other point mutations (A30P, E46K, H50Q, G51D and A53E) have since been shown to cause familial forms of Parkinson’s disease and…”
Backgroundα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 2×
“However, several of the antibodies produced to this end also detect oligomers composed of aggregated molecules of other amyloidogenic proteins, including A-beta, prion protein and lysozyme [73, 169].”
BackgroundAlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · Science · doi:10.1126/science.1227157 · Cited by 2,563
Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, G., Dobson, C. M., & Stefani, M. (2002) · Nature · doi:10.1038/416507a · Cited by 2,434 · cited 1×
“Together with direct evidence demonstrating the toxicity of oligomeric forms of a-syn, described in the following section, these observations suggest that Lewy bodies form as a protective mechanism by acting as a sink for toxic oligomers, sequestering them away from the cellular machinery [13, 108, 144].”
BackgroundDirect observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419 · cited 1×
“in order to sensitively detect protein levels [47] and were subsequently adapted for the detection of protein–protein interactions [56, 143].”
MethodGasque, G., Conway, S., Huang, J., Rao, Y., & Vosshall, L. B. (2013) · Scientific Reports · doi:10.1038/srep02120 · Cited by 2,292
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Li, J.-Y., Englund, E., Holton, J. L., Soulet, D., Hagell, P., Lees, A. J., Lashley, T., Quinn, N. P., Rehncrona, S., Björklund, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1746 · Cited by 1,845
Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease
Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B., & Olanow, C. W. (2008) · Nature Medicine · doi:10.1038/nm1747 · Cited by 1,722 · cited 1×
“patients, suggesting a-syn pathology had spread from diseased neurons in the recipient’s brain to the grafted neurons [75, 86].”
BackgroundCaughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · cited 1×
“However, several lines of evidence suggest that Lewy bodies themselves may be ‘innocent bystanders’ in Parkinson’s disease pathogenesis and that the toxic species of a-syn is in fact oligomers, which are precursors to Lewy bodies and not as readily detectable in histological sections [17].”
Background(1998) · Europe PMC (PubMed Central) · Cited by 1,594
NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded
Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., & Lansbury, P. T. (1996) · Biochemistry · doi:10.1021/bi961799n · Cited by 1,523
Protein detection using proximity-dependent DNA ligation assays
Fredriksson, S., Gullberg, M., Jarvius, J., Olsson, C., Pietras, K., Gústafsdóttir, S. M., Östman, A., & Landegren, U. (2002) · Nature Biotechnology · doi:10.1038/nbt0502-473 · Cited by 1,504
In vivo demonstration that α-synuclein oligomers are toxic
Winner, B., Jappelli, R., Maji, S. K., Desplats, P. A., Boyer, L., Aigner, S., Hetzer, C., Loher, T., Vilar, M., Campioni, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100976108 · Cited by 1,463
EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers
Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A., & Wanker, E. E. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1437 · Cited by 1,434
Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding
Saborio, G. P., Permanne, B., & Soto, C. (2001) · Nature · doi:10.1038/35081095 · Cited by 1,310
Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Zhang, W., Wang, T., Pei, Z., Miller, D. S., Wu, X., Block, M. L., Wilson, B., Zhang, W., Zhou, Y., Hong, J.-S., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-2751com · Cited by 1,265
α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation
Bartels, T., Choi, J. G., & Selkoe, D. J. (2011) · Nature · doi:10.1038/nature10324 · Cited by 1,263 · cited 1×
“1 3 that native a-syn exists physiologically as a folded helical tetramer that is resistant to fibrillization and thus distinct from pathological oligomers [8, 34, 96, 156].”
BackgroundCurcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254
α-Synuclein strains cause distinct synucleinopathies after local and systemic administration
Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., & Baekelandt, V. (2015) · Nature · doi:10.1038/nature14547 · Cited by 1,130 · cited 3×
“generated a-syn oligomers, fibrils (which by electron microscopy more closely resemble PFFs, as opposed to full-length fibrils) and ribbons (fibrils with twists), which were all capable of crossing the blood–brain barrier and distributing themselves within the central nervous system after intravenous injection in mice…”
BackgroundInfluentialKinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Luk, K. C., Kehm, V. M., Zhang, B., O’Brien, P., Trojanowski, J. Q., & Lee, V. M. Y. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112457 · Cited by 1,100
Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue
Lu, J.-X., Qiang, W., Yau, W.-M., Schwieters, C. D., Meredith, S. C., & Tycko, R. (2013) · Cell · doi:10.1016/j.cell.2013.08.035 · Cited by 1,097
Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease
Ibáñez, P., Bonnet, A.-M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., & Pollak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17104-3 · Cited by 1,044
EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity
Bieschke, J., Russ, J., Friedrich, R. P., Ehrnhoefer, D. E., Wobst, H., Neugebauer, K., & Wanker, E. E. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910723107 · Cited by 1,011
Luk, K. C., Song, C., O'Brien, P., Stieber, A., Branch, J. R., Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908005106 · Cited by 938
Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein
Cremades, N., Cohen, S. I. A., Deas, E., Abramov, A. Y., Chen, A. Y., Orte, A., Sandal, M., Clarke, R. W., Dunne, P., Aprile, F. A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.037 · Cited by 911
Lee, H.-J., Suk, J.-E., Patrick, C., Bae, E.-J., Cho, J.-H., Rho, S., Hwang, D., Masliah, E., & Lee, S.-J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.081125 · Cited by 877
Structural disorder of monomeric α-synuclein persists in mammalian cells
Theillet, F.-X., Binolfi, A., Bekei, B., Martorana, A., Rose, H. M., Stuiver, M., Verzini, S., Lorenz, D., van Rossum, M., Goldfarb, D., et al. (2016) · Nature · doi:10.1038/nature16531 · Cited by 868
Prion-like spreading of pathological α-synuclein in brain
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D. M. A., & Hasegawa, M. (2013) · Brain · doi:10.1093/brain/awt037 · Cited by 867
Kim, C., Ho, D.-H., Suk, J.-E., You, S., Michael, S., Kang, J., Joong Lee, S., Masliah, E., Hwang, D., Lee, H.-J., et al. (2013) · Nature Communications · doi:10.1038/ncomms2534 · Cited by 856 · cited 1×
“demonstrated that a-syn oligomers lead to microglial inflammatory responses via TLR2 activation [74].”
BackgroundExosomal cell-to-cell transmission of alpha synuclein oligomers
Danzer, K. M., Kranich, L. R., Ruf, W. P., Cagsal-Getkin, O., Winslow, A. R., Zhu, L., Vanderburg, C. R., & McLean, P. J. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-42 · Cited by 853
Hansen, C., Angot, E., Bergström, A.-L., Steiner, J. A., Pieri, L., Paul, G., Outeiro, T. F., Melki, R., Kallunki, P., Fog, K., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43366 · Cited by 842
Lashuel, H. A., Petre, B. M., Wall, J., Simon, M., Nowak, R. J., Walz, T., & Lansbury, P. T. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00735-0 · Cited by 805
Different Species of α-Synuclein Oligomers Induce Calcium Influx and Seeding
Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B., & Kostka, M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2617-07.2007 · Cited by 765
TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity
Decressac, M., Mattsson, B., Weikop, P., Lundblad, M., Jakobsson, J., & Björklund, A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305623110 · Cited by 753
El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715
G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndrome
Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., Pieri, L., Madiona, K., Dürr, A., Melki, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23894 · Cited by 711
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Mao, X., Ou, M. T., Karuppagounder, S. S., Kam, T.-I., Yin, X., Xiong, Y., Ge, P., Umanah, G. E., Brahmachari, S., Shin, J.-H., et al. (2016) · Science · doi:10.1126/science.aah3374 · Cited by 690
Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons
Guo, J. L., Covell, D. J., Daniels, J. P., Iba, M., Stieber, A., Zhang, B., Riddle, D. M., Kwong, L. K., Xu, Y., Trojanowski, J. Q., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.057 · Cited by 680
Alpha‐synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease
Appel‐Cresswell, S., Vilarino‐Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu‐Tu, C., Trinh, J., et al. (2013) · Movement Disorders · doi:10.1002/mds.25421 · Cited by 667
Schulz-Schaeffer, W. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0711-0 · Cited by 627
Alpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608
Self-citationKramer, M. L., & Schulz-Schaeffer, W. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4564-06.2007 · Cited by 571
Fauvet, B., Mbefo, M. K., Fares, M.-B., Desobry, C., Michael, S., Ardah, M. T., Tsika, E., Coune, P., Prudent, M., Lion, N., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.318949 · Cited by 566
Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., & Selkoe, D. J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00024-2 · Cited by 562
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
Pasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakkola, S., Lyytinen, J., Tienari, P. J., Pöyhönen, M., & Paetau, A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.024 · Cited by 536
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease
Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A. S., Kasai, T., Ishigami, N., Tamaoka, A., Nakagawa, M., & El-Agnaf, O. M. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fd613b · Cited by 527
Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease
Ryan, B. J., Hoek, S., Fon, E. A., & Wade-Martins, R. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.02.003 · Cited by 524 · cited 1×
“The high energy demands and increased oxidative stress of dopaminergic neurons render them particularly sensitive to mitochondrial dysfunction [133].”
BackgroundSelf-citationShahnawaz, M., Tokuda, T., Waragai, M., Mendez, N., Ishii, R., Trenkwalder, C., Mollenhauer, B., & Soto, C. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4547 · Cited by 489
A soluble α-synuclein construct forms a dynamic tetramer
Wang, W., Perovic, I., Chittuluru, J., Kaganovich, A., Nguyen, L. T. T., Liao, J., Auclair, J. R., Johnson, D., Landeru, A., Simorellis, A. K., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113260108 · Cited by 478
Chen, S. W., Drakulic, S., Deas, E., Ouberai, M., Aprile, F. A., Arranz, R., Ness, S., Roodveldt, C., Guilliams, T., De-Genst, E. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421204112 · Cited by 460
Chinta, S. J., Mallajosyula, J. K., Rane, A., & Andersen, J. K. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.09.061 · Cited by 449
A novel α-synuclein missense mutation in Parkinson disease
Proukakis, C., Dudzik, C. G., Brier, T., MacKay, D. S., Cooper, J. M., Millhauser, G. L., Houlden, H., & Schapira, A. H. (2013) · Neurology · doi:10.1212/wnl.0b013e31828727ba · Cited by 449
Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway
Lee, H.-J., Khoshaghideh, F., Patel, S., & Lee, S.-J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3809-03.2004 · Cited by 445
Karpinar, D. P., Balija, M. B. G., Kügler, S., Opazo, F., Rezaei‐Ghaleh, N., Wender, N., Kim, H., Taschenberger, G., Falkenburger, B. H., Heise, H., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.257 · Cited by 432
Ehrnhoefer, D. E., Duennwald, M., Markovic, P., Wacker, J. L., Engemann, S., Roark, M., Legleiter, J., Marsh, J. L., Thompson, L. M., Lindquist, S., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl210 · Cited by 414
Tunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes
Abounit, S., Bousset, L., Loria, F., Zhu, S., de Chaumont, F., Pieri, L., Olivo‐Marin, J., Melki, R., & Zurzolo, C. (2016) · The EMBO Journal · doi:10.15252/embj.201593411 · Cited by 414
Cytokine detection by antibody-based proximity ligation
Gullberg, M., Gústafsdóttir, S. M., Schallmeiner, E., Jarvius, J., Bjarnegård, M., Betsholtz, C., Landegren, U., & Fredriksson, S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400552101 · Cited by 411
Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M., Carvalho, F., Hyman, B. T., & McLean, P. J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001867 · Cited by 401
Proteasomal Inhibition by α-Synuclein Filaments and Oligomers
Lindersson, E., Beedholm, R., Højrup, P., Moos, T., Gai, W., Hendil, K. B., & Jensen, P. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306390200 · Cited by 397
Endoplasmic Reticulum Stress Is Important for the Manifestations of α-Synucleinopathy In Vivo
Colla, E., Coune, P., Liu, Y., Pletnikova, O., Troncoso, J. C., Iwatsubo, T., Schneider, B. L., & Lee, M. K. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5367-11.2012 · Cited by 389
Prion-like acceleration of a synucleinopathy in a transgenic mouse model
Mougenot, A.-L., Nicot, S., Bencsik, A., Morignat, E., Verchère, J., Lakhdar, L., Legastelois, S., & Baron, T. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.06.022 · Cited by 387
Tofaris, G. K., Razzaq, A., Ghetti, B., Lilley, K. S., & Spillantini, M. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308041200 · Cited by 361
Neumann, M., Kahle, P. J., Giasson, B. I., Ozmen, L., Borroni, E., Spooren, W., Müller, V., Odoy, S., Fujiwara, H., Hasegawa, M., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15777 · Cited by 355
Parkkinen, L., Pirttilä, T., & Alafuzoff, I. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0346-6 · Cited by 354
Protein Misfolding and Neurodegeneration
Soto, C., & Estrada, L. D. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.56 · Cited by 352
Accumulation of Phosphorylated α-Synuclein in Aging Human Brain
Saito, Y., Kawashima, A., Ruberu, N. N., Fujiwara, H., Koyama, S., Sawabe, M., Arai, T., Nagura, H., Yamanouchi, H., Hasegawa, M., et al. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.6.644 · Cited by 351
Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model
Janezic, S., Threlfell, S., Dodson, P. D., Dowie, M. J., Taylor, T. N., Potgieter, D., Parkkinen, L., Senior, S. L., Anwar, S., Ryan, B., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309143110 · Cited by 344 · cited 1×
“Not only are they present at the degenerating regions in Parkinson’s disease patients [140, 151] and transgenic models [53, 64, 66, 121], but direct experimental evidence shows their toxic properties.”
BackgroundSelf-citationAlpha-Synuclein Oligomers—Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders
Ingelsson, M. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00408 · Cited by 344
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Bae, E.-J., Lee, H.-J., Rockenstein, E., Ho, D.-H., Park, E.-B., Yang, N.-Y., Desplats, P., Masliah, E., & Lee, S.-J. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1292-12.2012 · Cited by 339
Properties of native brain α-synuclein
Burré, J., Vivona, S., Diao, J., Sharma, M., Brunger, A. T., & Südhof, T. C. (2013) · Nature · doi:10.1038/nature12125 · Cited by 339
Saá, P., Castilla, J., & Soto, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603964200 · Cited by 328
Colla, E., Jensen, P. H., Pletnikova, O., Troncoso, J. C., Glabe, C., & Lee, M. K. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5368-11.2012 · Cited by 323
Games, D., Valera, E., Spencer, B., Rockenstein, E., Mante, M., Adame, A., Patrick, C., Ubhi, K., Nuber, S., Sacayon, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5314-13.2014 · Cited by 322
Protein Misfolding, Amyloid Formation, and Neurodegeneration
Muchowski, P. J. (2002) · Neuron · doi:10.1016/s0896-6273(02)00761-4 · Cited by 308
Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking
Choi, B.-K., Choi, M.-G., Kim, J.-Y., Yang, Y., Lai, Y., Kweon, D.-H., Lee, N. K., & Shin, Y.-K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218424110 · Cited by 300
Sinha, S., Lopes, D. H. J., Du, Z., Pang, E. S., Shanmugam, A., Lomakin, A., Talbiersky, P., Tennstaedt, A., McDaniel, K., Bakshi, R., et al. (2011) · Journal of the American Chemical Society · doi:10.1021/ja206279b · Cited by 299
Gosavi, N., Lee, H.-J., Lee, J. S., Patel, S., & Lee, S.-J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208194200 · Cited by 294
Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo
Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M. G., & Feany, M. B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0285-07.2007 · Cited by 292
α-Synuclein and dopamine at the crossroads of Parkinson's disease
Venda, L. L., Cragg, S. J., Buchman, V. L., & Wade-Martins, R. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.09.004 · Cited by 285
Self-citationMeng, F., Abedini, A., Plesner, A., Verchere, C. B., & Raleigh, D. P. (2010) · Biochemistry · doi:10.1021/bi100939a · Cited by 282
Structural basis of synaptic vesicle assembly promoted by α-synuclein
Fusco, G., Pape, T., Stephens, A. D., Mahou, P., Costa, A. R., Kaminski, C. F., Kaminski Schierle, G. S., Vendruscolo, M., Veglia, G., Dobson, C. M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12563 · Cited by 280
Luth, E. S., Stavrovskaya, I. G., Bartels, T., Kristal, B. S., & Selkoe, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.545749 · Cited by 279
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Majbour, N. K., Vaikath, N. N., van Dijk, K. D., Ardah, M. T., Varghese, S., Vesterager, L. B., Montezinho, L. P., Poole, S., Safieh-Garabedian, B., Tokuda, T., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0072-9 · Cited by 277
Roberts, R. F., Wade-Martins, R., & Alegre-Abarrategui, J. (2015) · Brain · doi:10.1093/brain/awv040 · Cited by 271
Self-citationTransfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice
Rey, N. L., Petit, G. H., Bousset, L., Melki, R., & Brundin, P. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1160-3 · Cited by 267
Curcumin inhibits aggregation of α-synuclein
Pandey, N., Strider, J., Nolan, W. C., Yan, S. X., & Galvin, J. E. (2008) · Acta Neuropathologica · doi:10.1007/s00401-007-0332-4 · Cited by 263
Biochemical Characterization of the Core Structure of α-Synuclein Filaments
Miake, H., Mizusawa, H., Iwatsubo, T., & Hasegawa, M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110551200 · Cited by 260
Wen, C., Ogura, Y., & Matsushima, T. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00476 · Cited by 259
α-Synuclein gene duplication is present in sporadic Parkinson disease
Ahn, T. B., Kim, S. Y., Kim, J. Y., Park, S. S., Lee, D. S., Min, H. J., Kim, Y. K., Kim, S. E., Kim, J. M., Kim, H. J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000271080.53272.c7 · Cited by 249
Propagation of prions causing synucleinopathies in cultured cells
Woerman, A. L., Stöhr, J., Aoyagi, A., Rampersaud, R., Krejciova, Z., Watts, J. C., Ohyama, T., Patel, S., Widjaja, K., Oehler, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513426112 · Cited by 247
40-residue beta-amyloid fibril derived from Alzheimer's disease brain
Lu, J., Qiang, W., Meredith, S. C., Yau, W., Schweiters, C. D., & Tycko, R. (2013) · Cell · doi:10.2210/pdb2m4j/pdb · Cited by 246
Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Odoy, S., Okamoto, N., Jacobsen, H., Iwatsubo, T., Trojanowski, J. Q., Takahashi, H., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63072-6 · Cited by 239
Lindström, V., Gustafsson, G., Sanders, L. H., Howlett, E. H., Sigvardson, J., Kasrayan, A., Ingelsson, M., Bergström, J., & Erlandsson, A. (2017) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2017.04.009 · Cited by 233
Mandler, M., Valera, E., Rockenstein, E., Weninger, H., Patrick, C., Adame, A., Santic, R., Meindl, S., Vigl, B., Smrzka, O., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1256-4 · Cited by 229
Dettmer, U., Newman, A. J., Luth, E. S., Bartels, T., & Selkoe, D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.403311 · Cited by 221
Cell-produced α-synuclein oligomers are targeted to, and impair, the 26S proteasome
Emmanouilidou, E., Stefanis, L., & Vekrellis, K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.07.008 · Cited by 221
Lee, J.-G., Takahama, S., Zhang, G., Tomarev, S. I., & Ye, Y. (2016) · Nature Cell Biology · doi:10.1038/ncb3372 · Cited by 221
Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment
Poehler, A.-M., Xiang, W., Spitzer, P., May, V. E. L., Meixner, H., Rockenstein, E., Chutna, O., Outeiro, T. F., Winkler, J., Masliah, E., et al. (2014) · Autophagy · doi:10.4161/auto.36436 · Cited by 212
Ghosh, D., Singh, P. K., Sahay, S., Jha, N. N., Jacob, R. S., Sen, S., Kumar, A., Riek, R., & Maji, S. K. (2015) · Scientific Reports · doi:10.1038/srep09228 · Cited by 211
Evolving basic, pathological and clinical concepts in PD
Kalia, L. V., & Lang, A. E. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.249 · Cited by 206
Lewy body cortical involvement may not always predict dementia in Parkinson's disease
Colosimo, C. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.7.852 · Cited by 200
Curcumin reduces α-synuclein induced cytotoxicity in Parkinson's disease cell model
Wang, M. S., Boddapati, S., Emadi, S., & Sierks, M. R. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-57 · Cited by 197
Park, M. J., Cheon, S.-M., Bae, H.-R., Kim, S.-H., & Kim, J. W. (2011) · Journal of Clinical Neurology · doi:10.3988/jcn.2011.7.4.215 · Cited by 195
Ca2+ is a key factor in α-synuclein-induced neurotoxicity
Angelova, P. R., Ludtmann, M. H. R., Horrocks, M. H., Negoda, A., Cremades, N., Klenerman, D., Dobson, C. M., Wood, N. W., Pavlov, E. V., Gandhi, S., et al. (2016) · Journal of Cell Science · doi:10.1242/jcs.180737 · Cited by 194
Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity
Luk, K. C., Covell, D. J., Kehm, V. M., Zhang, B., Song, I. Y., Byrne, M. D., Pitkin, R. M., Decker, S. C., Trojanowski, J. Q., & Lee, V. M.-Y. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.053 · Cited by 191 · cited 1×
“[92] where they showed that mouse and human a-syn cross-seeded with reduced efficiency, due to sequence differences.”
BackgroundA longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease
Foulds, P. G., Diggle, P., Mitchell, J. D., Parker, A., Hasegawa, M., Masuda-Suzukake, M., Mann, D. M. A., & Allsop, D. (2013) · Scientific Reports · doi:10.1038/srep02540 · Cited by 185
Lu, J.-H., Tan, J.-Q., Durairajan, S. S. K., Liu, L.-F., Zhang, Z.-H., Ma, L., Shen, H.-M., Chan, H. Y. E., & Li, M. (2012) · Autophagy · doi:10.4161/auto.8.1.18313 · Cited by 184
Age-dependent defects of alpha-synuclein oligomer uptake in microglia and monocytes
Bliederhaeuser, C., Grozdanov, V., Speidel, A., Zondler, L., Ruf, W. P., Bayer, H., Kiechle, M., Feiler, M. S., Freischmidt, A., Brenner, D., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1504-2 · Cited by 180
Putcha, P., Danzer, K. M., Kranich, L. R., Scott, A., Silinski, M., Mabbett, S., Hicks, C. D., Veal, J. M., Steed, P. M., Hyman, B. T., et al. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158436 · Cited by 179
CHIP Targets Toxic α-Synuclein Oligomers for Degradation
Tetzlaff, J. E., Putcha, P., Outeiro, T. F., Ivanov, A., Berezovska, O., Hyman, B. T., & McLean, P. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802283200 · Cited by 175
Frigerio, R., Fujishiro, H., Ahn, T.-B., Josephs, K. A., Maraganore, D. M., DelleDonne, A., Parisi, J. E., Klos, K. J., Boeve, B. F., Dickson, D. W., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.05.019 · Cited by 173
α-Synuclein Oligomers Impair Neuronal Microtubule-Kinesin Interplay
Prots, I., Veber, V., Brey, S., Campioni, S., Buder, K., Riek, R., Böhm, K. J., & Winner, B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.451815 · Cited by 170
Kovacs, G. G., Wagner, U., Dumont, B., Pikkarainen, M., Osman, A. A., Streichenberger, N., Leisser, I., Verchère, J., Baron, T., Alafuzoff, I., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0964-x · Cited by 169
Park, J., Paik, S. R., Jou, I., & Park, S. M. (2008) · Glia · doi:10.1002/glia.20691 · Cited by 165
Gómez-Tortosa, E., Newell, K., Irizarry, M. C., Sanders, J. L., & Hyman, B. T. (2000) · Acta Neuropathologica · doi:10.1007/s004010051135 · Cited by 162
Structural and functional properties of prefibrillar α-synuclein oligomers
Pieri, L., Madiona, K., & Melki, R. (2016) · Scientific Reports · doi:10.1038/srep24526 · Cited by 162
A Novel “Molecular Tweezer” Inhibitor of α-Synuclein Neurotoxicity in Vitro and in Vivo
Prabhudesai, S., Sinha, S., Attar, A., Kotagiri, A., Fitzmaurice, A. G., Lakshmanan, R., Ivanova, M. I., Loo, J. A., Klärner, F.-G., Schrader, T., et al. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0105-1 · Cited by 161
A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease
Wrasidlo, W., Tsigelny, I. F., Price, D. L., Dutta, G., Rockenstein, E. M., Schwarz, T. C., Ledolter, K., Bonhaus, D. W., Paulino, A., Eleuteri, S., et al. (2016) · Brain · doi:10.1093/brain/aww238 · Cited by 158
Vernon, A. C., Johansson, S., & Modo, M. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-1 · Cited by 153
Vaikath, N. N., Majbour, N. K., Paleologou, K. E., Ardah, M. T., van Dam, E., van de Berg, W. D. J., Forrest, S. L., Parkkinen, L., Gai, W., Hattori, N., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.04.009 · Cited by 152
Bacterial in-cell NMR of human α-synuclein: a disordered monomer by nature?
Binolfi, A., Theillet, F., & Selenko, P. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120096 · Cited by 152
Lindström, V., Fagerqvist, T., Nordström, E. K. L., Eriksson, F., Lord, A., Tucker, S. M., Andersson, J., Johannesson, M., Schell, H., Kahle, P. J., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.009 · Cited by 145
Näsström, T., Fagerqvist, T., Barbu, M., Karlsson, M., Nikolajeff, F. K., Kasrayan, A., Ekberg, M., Lannfelt, L., Ingelsson, M., & Bergström, J. J. E. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.11.027 · Cited by 143
G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies
Gaig, C., Martí, M. J., Ezquerra, M., Rey, M. J., Cardozo, A., & TOLOSA, E. S. (2007) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.107904 · Cited by 137
DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function
Plotegher, N., Berti, G., Ferrari, E., Tessari, I., Zanetti, M., Lunelli, L., Greggio, E., Bisaglia, M., Veronesi, M., Girotto, S., et al. (2017) · Scientific Reports · doi:10.1038/srep40699 · Cited by 133
Kovács, G. G., Breydo, L., Green, R. J., Kis, V., Puska, G., Lőrincz, P., Perju‐Dumbrava, L., Giera, R., Pirker, W., Lutz, M. I., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.05.020 · Cited by 132
Sánchez-Guajardo, V., Annibali, A., Jensen, P. H., & Romero‐Ramos, M. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31829768d2 · Cited by 117
Oligomeric α-synuclein inhibits tubulin polymerization
Chen, L., Jin, J., Davis, J., Zhou, Y. F., Wang, Y., Liu, J., Lockhart, P. J., & Zhang, J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.163 · Cited by 116
Alpha-synuclein activates BV2 microglia dependent on its aggregation state
Hoffmann, A., Ettle, B., Bruno, A., Kulinich, A. O., Hoffmann, A.-C., von Wittgenstein, J., Winkler, J., Xiang, W., & Schlachetzki, J. C. M. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.109 · Cited by 111
Genetic neuropathology of Parkinson's disease.
Cookson, M., Hardy, J., & Lewis, P. A. (2008) · PubMed Central · Cited by 108
Molecular Chaperones as Rational Drug Targets for Parkinsons Disease Therapeutics
Kalia, S. K., Kalia, L. V., & McLean, P. J. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710793237386 · Cited by 108
α-Synuclein is a Novel Microtubule Dynamase
Cartelli, D., Aliverti, A., Barbiroli, A. G., Santambrogio, C., Ragg, E. M., Casagrande, F., Cantele, F., Beltramone, S., Marangon, J., Gregorio, C. D., et al. (2016) · Scientific Reports · doi:10.1038/srep33289 · Cited by 105
Protection of primary neurons and mouse brain from Alzheimer's pathology by molecular tweezers
Attar, A., Ripoli, C., Riccardi, E., Maiti, P., Puma, D. D. L., Liu, T., Hayes, J. D., Jones, M. R., Lichti-Kaiser, K., Yang, F., et al. (2012) · Brain · doi:10.1093/brain/aws289 · Cited by 104
Plotegher, N., Gratton, E., & Bubacco, L. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.02.013 · Cited by 103
Tanji, K., Mori, F., Mimura, J., Itoh, K., Kakita, A., Takahashi, H., & Wakabayashi, K. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0676-z · Cited by 102
Helwig, M., Klinkenberg, M., Rusconi, R., Musgrove, R. E., Majbour, N. K., El‐Agnaf, O. M. A., Ulusoy, A., & Monte, D. A. D. (2015) · Brain · doi:10.1093/brain/awv376 · Cited by 102
Wahl, M., Link, H., Alexandridis, N., Thomason, J. C., Cifuentes, M., Costello, M. J., da Gama, B. A. P., Hillock, K., Hobday, A. J., Kaufmann, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019514 · Cited by 101
Wilms, H., Rosenstiel, P. C., Romero‐Ramos, M., Arlt, A., Schäfer, H., Seegert, D., Kahle, P. J., Odoy, S., Claasen, J.-H., Holzknecht, C., et al. (2009) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200902200405 · Cited by 93
Fagerqvist, T., Lindström, V., Nordström, E. K. L., Lord, A., Tucker, S. M., Su, X., Sahlin, C., Kasrayan, A., Andersson, J., Welander, H., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12175 · Cited by 93
Perfettini, J., Nardacci, R., Bourouba, M., Subra, F., Gros, L., Séror, C., Manic, G., Rosselli, F., Amendola, A., Masdehors, P., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002458 · Cited by 84
Luth, E. S., Bartels, T., Dettmer, U., Kim, N. C., & Selkoe, D. J. (2014) · Biochemistry · doi:10.1021/bi501188a · Cited by 79
Direct detection of alpha synuclein oligomers in vivo
Dimant, H., Kalia, S. K., Kalia, L. V., Zhu, L., Kibuuka, L. N., Ebrahimi‐Fakhari, D., McFarland, N. R., Fan, Z., Hyman, B. T., & McLean, P. J. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-6 · Cited by 77
Widespread and abundant α‐synuclein pathology in a neurologically unimpaired subject
Parkkinen, L., Pirttilä, T., Tervahauta, M., & Alafuzoff, I. I. (2005) · Neuropathology · doi:10.1111/j.1440-1789.2005.00644.x · Cited by 77
Amyloid Oligomer Conformation in a Group of Natively Folded Proteins
Yoshiike, Y., Minai, R., Matsuo, Y., Chen, Y., Kimura, T., & Takashima, A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003235 · Cited by 76
Kara, E., Kiely, A. P., Proukakis, C., Giffin, N., Love, S., Hehir, J., Rantell, K. R., Pandraud, A., Hernandez, D. G., Nacheva, E. P., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.994 · Cited by 73
Antibodies against Alpha-Synuclein Reduce Oligomerization in Living Cells
Näsström, T., Gonçalves, S. A., Sahlin, C., Nordström, E. K. L., Sundquist, V. S., Lannfelt, L., Bergström, J. J. E., Outeiro, T. F., & Ingelsson, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027230 · Cited by 71
Williams, S. M., Schulz, P., & Sierks, M. R. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.13056 · Cited by 70
Jung, B. C., Lim, Y.-J., Bae, E.-J., Lee, J. S., Choi, M. S., Lee, M. K., Lee, H.-J., Kim, Y. S., & Lee, S. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.1 · Cited by 66
Topography of FUS pathology distinguishes late-onset BIBD from aFTLD-U
Lee, E. B., Russ, J., Jung, H., Elman, L. B., Chahine, L. M., Kremens, D. E., Miller, B. L., Coslett, H. B., Trojanowski, J. Q., Deerlin, V. M. V., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-9 · Cited by 61
Correction: Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
Outeiro, T. F., Putcha, P., Tetzlaff, J. E., Spoelgen, R., Koker, M., Carvalho, F., Hyman, B. T., & McLean, P. J. (2008) · PLoS ONE · doi:10.1371/annotation/9282f173-df82-4b70-9120-b4e62b3dacb1 · Cited by 56
McFarland, N. R., Dimant, H., Kibuuka, L. N., Ebrahimi‐Fakhari, D., Desjardins, C. A., Danzer, K. M., Danzer, M. A., Fan, Z., Schwarzschild, M. A., Hirst, W. D., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086048 · Cited by 55
Differential Activation of the ER Stress Factor XBP1 by Oligomeric Assemblies
Castillo‐Carranza, D. L., Zhang, Y., Guerrero‐Munoz, M. J., Kayed, R., Rincón-Limas, D. E., & Fernández-Fúnez, P. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0780-7 · Cited by 53
Intracellular soluble α‐synuclein oligomers reduce pyramidal cell excitability
Kaufmann, T. J., Harrison, P. M., Richardson, M. J. E., Pinheiro, T. J. T., & Wall, M. J. (2016) · The Journal of Physiology · doi:10.1113/jp271968 · Cited by 53
Du, Y., Wang, F., Zou, J., Le, W., Dong, Q., Wang, Z., Shen, F., Yu, L., & Li, Y. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.029 · Cited by 46
Sensitive detection of Aβ protofibrils by proximity ligation - relevance for Alzheimer's disease
Kamali‐Moghaddam, M., Pettersson, F. E., Wu, D., Englund, H., Darmanis, S., Lord, A., Tavoosidana, G., Sehlin, D., Gustafsdottir, S., Nilsson, L. N. G., et al. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-124 · Cited by 46
Bild, D. E., McClelland, R. L., Kaufman, J. D., Blumenthal, R. S., Burke, G. L., Carr, J. J., Post, W. S., Register, T. C., Shea, S., & Szklo, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094916 · Cited by 36
Zhang, X., Sun, X., Xue, D., Liu, D., Hu, X.-Y., Zhao, M., Yang, S., Yang, Y., Xia, Y., Wang, Y., et al. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.09.005 · Cited by 30
Fagerqvist, T., Näsström, T., Ihse, E., Lindström, V., Sahlin, C., Tucker, S. M. F., Kasaryan, A., Karlsson, M., Nikolajeff, F. K., Schell, H., et al. (2013) · Amyloid · doi:10.3109/13506129.2013.835726 · Cited by 30
Ysselstein, D., Dehay, B., Costantino, I. M., McCabe, G. P., Frosch, M. P., George, J. M., Bézard, E., & Rochet, J. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0403-7 · Cited by 30
Lewis, K. A., Yaeger, A., Demartino, G., & Thomas, P. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9258-y · Cited by 26
Animal models for prion-like diseases
Fernández‐Borges, N., Eraña, H., Venegas, V., Elezgarai, S. R., Harrathi, C., & Castilla, J. (2015) · Virus Research · doi:10.1016/j.virusres.2015.04.014 · Cited by 16
Williams, S. M., Schulz, P., & Sierks, M. R. (2014) · Biotechnology Progress · doi:10.1002/btpr.1987 · Cited by 16
Rewiring macrophages for anti-tumour immunity
Lee, Y., & Biswas, S. K. (2016) · Nature Cell Biology · doi:10.1038/ncb3384 · Cited by 11
Dickson, D. W., & Murray, M. E. (2015) · Brain · doi:10.1093/brain/awv097 · Cited by 8
Sieling, F. H., Simmers, J., Prinz, A. A., & Nargeot, R. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-s1-p1 · Cited by 4
ExPLAining early synucleinopathies: Figure 1
Dettmer, U., & Bartels, T. (2015) · Brain · doi:10.1093/brain/awv099 · Cited by 3
Seeing I s B elieving: A lpha‐ S ynuclein Ol igomers in P arkinson's D isease B rain
Williams‐Gray, C. H. (2015) · Movement Disorders · doi:10.1002/mds.26335 · Cited by 2
An A‐PLAuse to a new assay that unveils previously undetected alpha‐synucleinopathies
Hernández, L. F. (2016) · Movement Disorders · doi:10.1002/mds.26514 · Cited by 1
Cited by
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Phase separation and neurodegenerative diseases: a disturbance in the force
Zbinden, A., Pérez-Berlanga, M., De Rossi, P., & Polymenidou, M. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.09.014 · Cited by 500
Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
Gómez-Benito, M., Granado, N., García-Sanz, P., Michel, A., Dumoulin, M., & Moratalla, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00356 · Cited by 437
Dementia with Lewy bodies: an update and outlook
Outeiro, T. F., Koss, D. J., Erskine, D., Walker, L., Kurzawa-Akanbi, M., Burn, D., Donaghy, P., Morris, C., Taylor, J.-P., Thomas, A., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0306-8 · Cited by 381
Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease
Fields, C. R., Bengoa-Vergniory, N., & Wade-Martins, R. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00299 · Cited by 328
Self-citation
Metadata
- Authors
- Bengoa-Vergniory, N., Roberts, R. F., Wade-Martins, R., & Alegre-Abarrategui, J.
- Venue
- Acta Neuropathologica
- Published
- 2017-08-12
- Volume
- 134
- Issue
- 6
- Pages
- 819-838
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2745164635
- Cited by
- 338
- References
- 180
- FWCI
- 17.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.